FCER2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4421135	0.80	15/20
SCHEMBL3498528	0.60	15/20
Batimastat (SCHEMBL4332)	1.00	13/20
Batimastat (SCHEMBL4333)	1.00	13/20
SCHEMBL3498576	0.81	13/20
SCHEMBL4986992	0.73	13/20
SCHEMBL2929780	0.64	13/20
SCHEMBL3503805	0.61	13/20
Batimastat (SCHEMBL2777573)	0.80	12/20
SCHEMBL3503807	0.57	12/20
SCHEMBL2927885	0.71	11/20
SCHEMBL134501	0.65	11/20
SCHEMBL4420629	0.60	10/20
SCHEMBL2184039	0.66	7/20
SCHEMBL3498530	0.59	7/20
SCHEMBL1668258	0.77	6/20
SCHEMBL5177480	0.61	6/20
SCHEMBL4840160	0.58	6/20
SCHEMBL4847121	0.58	6/20
SCHEMBL4847134	0.58	6/20

Clinical trials — most relevant to FCER2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)	PHASE4	COMPLETED
The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma	PHASE4	COMPLETED
Effect of Omalizumab on Expression of IgE Receptors in Adults With Severe, Inadequately Controlled Allergic Asthma	PHASE4	COMPLETED
mRNA Expression as a Biomarker of Omalizumab Response	PHASE4	UNKNOWN
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)	PHASE4	COMPLETED
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients	PHASE2/PHASE3	COMPLETED
Allergic Rhinitis, Immunotherapy and Vitamin d	PHASE2/PHASE3	UNKNOWN
Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children	PHASE3	UNKNOWN
Effect of Anti-IgE in Chronic Urticaria	PHASE2	COMPLETED
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	PHASE2	COMPLETED
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction	PHASE2	COMPLETED
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Post IVIG Medication in Children With Immune Thrombocytopenia	PHASE1	UNKNOWN
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases	PHASE1	COMPLETED
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma	PHASE1	COMPLETED
Preventive IVIG Therapy for Congenital Heart Block	EARLY_PHASE1	COMPLETED
Contribution of Nasal IgE Production to the Boost of Systemic Allergen-specific IgE Upon Nasal Allergen Contact	nan	RECRUITING
Study if the Presence of Functional FcERI/RII on the Surface of Human Blood Platelet	nan	UNKNOWN
Correlation Between IgE Parameters and the Response to Omalizumab in Subjects With Severe Asthma	nan	WITHDRAWN
FGL2/Fibroleukin and Hepatitis C Virus Recurrence Post Liver Transplantation	nan	UNKNOWN
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation	nan	COMPLETED
Frequency of FCGR3A Gene Polymorphisms in Patients With Neuromyelitis Optica Spectrum Disorders, Anti-oligodendrocyte Myelin Protein Antibody Disease, and Multiple Sclerosis.	nan	RECRUITING
The Effect of Omalizumab on Responses to Cat Allergen Challenge	nan	COMPLETED
Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy	nan	COMPLETED
Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer	nan	RECRUITING
Prognostic Value of CD64 Marker for Patients in Intensive Care Unit	nan	UNKNOWN
Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra	nan	UNKNOWN
Studying Blood and DNA Samples From Patients With Breast Cancer Treated With Chemotherapy With or Without Trastuzumab	nan	COMPLETED
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus	nan	COMPLETED
Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a FCER2 binder may also engage these)

Protein	Name	Similarity
P20693	—	0.996	P20693 →
Q8MIS5	—	0.991	Q8MIS5 →
Q8CJ91	—	0.985	Q8CJ91 →
Q6ZS10	—	0.984	Q6ZS10 →
Q91ZW8	—	0.984	Q91ZW8 →
P70194	—	0.982	P70194 →
P02707	—	0.981	P02707 →
Q9Z0K5	—	0.981	Q9Z0K5 →
Q91ZW7	—	0.981	Q91ZW7 →
Q91ZX1	—	0.981	Q91ZX1 →
Q9Y264	—	0.981	Q9Y264 →
Q5RFW0	—	0.980	Q5RFW0 →
Q8N1N0	—	0.980	Q8N1N0 →
P41159	—	0.980	P41159 →
P30204	—	0.980	P30204 →
Q64335	—	0.980	Q64335 →
P10716	—	0.980	P10716 →
Q05585	—	0.980	Q05585 →
Q01151	—	0.980	Q01151 →
Q96PD2	—	0.979	Q96PD2 →
Q9H8L6	—	0.979	Q9H8L6 →
P60883	—	0.979	P60883 →
Q9ET61	—	0.979	Q9ET61 →
Q8HY02	—	0.979	Q8HY02 →
Q9Z1P5	—	0.979	Q9Z1P5 →
Q9D9J7	—	0.979	Q9D9J7 →
Q6ZU45	—	0.979	Q6ZU45 →
Q86T13	—	0.979	Q86T13 →
Q8VCP9	—	0.978	Q8VCP9 →
Q8N6P7	—	0.978	Q8N6P7 →